SenesTech, Inc. (NASDAQ: SNES) was founded in July 2004 and is headquartered in Flagstaff, Arizona, USA. It has 40 full-time employees. It is a biotechnology company specializing in birth control and management of animal populations. Currently, the company has developed and is Seek to use birth control to commercially manage the proprietary technology of animal pest populations on a global scale.
SenesTech, Inc. (SNES):
Founded by two scientists who love animals, SenesTech is a biotechnology platform and research company that has developed an innovative technology to manage animal populations through birth control. The non-fatal treatment developed by SenesTech is more effective, more humane, and less harmful to the environment than traditional management methods.
SenesTech’s first product applies its revolutionary technology to a global problem that has continued since the Middle Ages: the spread of rats (rat infestation) in urban and agricultural environments. SenesTech’s innovative compounds are easily consumed by rats and make them no longer reproduce, with no other observable side effects. Rodents live normally for 8-12 months (lifespan) without producing offspring. Since rapid reproduction is the root cause of rat infection, this has introduced a new model for the science of pest control.
When used as directed, SenesTech’s species-specific preparations are environmentally neutral, do not affect non-target animals, and have no effect on human health or fertility.
Currently, SenesTech is stepping up the EPA (United States Environmental Protection Agency) registration process (update: ContraPest has been approved by the EPA on August 2, 2016), after which it will be available for commercial sales. At the same time, recent tests have received positive feedback from subways in New York, Boston Metropolitans, and rice fields in Southeast Asia. Once SenesTech’s EPA registration is completed, the road to commercialization will accelerate, and cooperation with major manufacturers’ strategic partners and leading pest control service providers seeking to replace traditional pest management methods.
The science behind SenesTech’s products is mature. In the long term, SenesTech preparations may become spray sterilization and non-surgical solutions for cats and dogs.
SenesTech, Inc. (SNES) product:
SenesTech’s first birth control candidate product, ContraPest, will be marketed to control rat births. The company is conducting regulatory approval review procedures for ContraPest in various jurisdictions, including the United States, India, Argentina and the European Union (EU).
On August 23, 2015, SenesTech submitted a ContraPest registration application to the U.S. Environmental Protection Agency (EPA) and obtained EPA registration approval on August 2, 2016. ContraPest is the first birth control product approved by the EPA for rodent population management.
However, before SenesTech can start selling ContraPest in the United States, the company must also obtain registration from various state regulatory agencies. So far, SenesTech has received ContraPest registrations in 14 states and the District of Columbia, and other applications are pending.
SenesTech, Inc. (SNES) investment:
SenesTech, Inc. (NASDAQ:SNES) was listed on NASDAQ on December 8, 2016, with an issue price of US$8. It issued 1.875 million shares and raised US$15 million. The stock code: SNES.